Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SRNG Stock Summary
In the News
Ginkgo Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) Investors
RADNOR, Pa., Oct. 8, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo") f/k/a Soaring Eagle Acquisition Corp. (Nasdaq: SRNG) ("Soaring Eagle").
DNA Stock Cooks Up 10% Gains on Ginkgo Biowork's First Trading Day
Ginkgo Bioworks knows about growth and so far, it seems as though DNA stock does as well as it kicks off under an aptly titled ticker. The post DNA Stock Cooks Up 10% Gains on Ginkgo Biowork's First Trading Day appeared first on InvestorPlace.
Ginkgo Bioworks to Begin Trading Today as NYSE: DNA with Over $1.6 Billion in Proceeds
BOSTON, Sept. 17, 2021 /PRNewswire/ -- Ginkgo Bioworks, Inc. ("Ginkgo") and Soaring Eagle Acquisition Corp. (Nasdaq: SRNG) ("Soaring Eagle"), a special purpose acquisition company, today announced the closing of their previously announced business combination.
Dear SRNG Stock Fans, Mark Your Calendars for Ginkgo Bioworks' Debut on Sept. 17
Soaring Eagle Acquisition is about to complete its merger with Ginkgo Bioworks, and SRNG stock is reacting well. Here's why.
All Aboard For The BioRevolution
BioRevolution is a new and rapidly growing set of tools that are increasingly allowing us to read, write and hack that code of life with greater speed and precision and a rapidly decreasing cost. Health care is the most mature sector of those we are investing in, and even in health care, it's still early.
Is Ginkgo Bioworks Worth the Hype?
The synthetic biology company is going public through one of the largest SPAC mergers in history. Is the stock worth paying up for?
3 Life Science Stocks Cathy Wood's Buying Hand Over Fist Right Now
ARK Invest made multiple purchases of these stocks last week.
Soaring Eagle Announces Extraordinary General Meeting Date for Proposed Business Combination with Ginkgo
NEW YORK--(BUSINESS WIRE)-- #ginkgobioworks--Soaring Eagle Acquisition Corp., a Cayman Islands exempted company limited by shares (the “Company” or “Soaring Eagle”) (Nasdaq: SRNG.U, SRNG, SRNG WS), announced today that it has scheduled the extraordinary general meeting of the Company's shareholders (the "Special Meeting") in connection with its business combination (the "Business Combination") with Ginkgo Bioworks, Inc. to be held on September 14, 2021. Notice of the Special Meeting and a proxy statement/prospec
Cathie Wood's Ark Invest just doubled a multi-million-share position in a SPAC merging with Ginkgo Bioworks
Ark Invest first began purchasing shares of the Ginkgo Bioworks SPAC on August 3 and now owns 14.5 million shares worth about $150 million.
Soaring Eagle: SPAC Merger With Promising Synthetic Biology Specialist, Ginkgo Bioworks
Ginkgo Bioworks, Inc. and Soaring Eagle Acquisition Corp., a special purpose acquisition company, have announced their $17B merger transaction will finalize in Q3'21 resulting in Ginkgo earning a $15B EV. Ginkgo Bioworks is a high-growth analytical biotechnology company applying automation for contract-based cell engineering utilizing a combination of computational and synthetic biological practices.
SRNG Financial details
SRNG Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
Metric | History | 2020-12-31 |
---|---|---|
2.02K | ||
Revenue per share | 0 | |
Net income per share | 0 | |
Operating cash flow per share | 0 | |
Free cash flow per share | 0 | |
Cash per share | 0 | |
Book value per share | 0 | |
Tangible book value per share | 0 | |
Share holders equity per share | 0 | |
Interest debt per share | 0 | |
Market cap | 0 | |
Enterprise value | 300K | |
P/E ratio | 0 | |
Price to sales ratio | 0 | |
POCF ratio | 0 | |
PFCF ratio | 0 | |
P/B Ratio | 0 | |
PTB ratio | 0 | |
EV to sales | 0 | |
Enterprise value over EBITDA | 0 | |
EV to operating cash flow | 0 | |
EV to free cash flow | 0 | |
Earnings yield | 0 | |
Free cash flow yield | 0 | |
Debt to equity | 15 | |
Debt to assets | 0.24 | |
Net debt to EBITDA | 0 | |
Current ratio | 0 | |
Interest coverage | 0 | |
Income quality | 0 | |
Dividend Yield | 0 | |
Payout ratio | 0 | |
Sales general and administrative to revenue | 0 | |
Research and developement to revenue | 0 | |
Intangibles to total assets | 0 | |
Capex to operating cash flow | 0 | |
Capex to revenue | 0 | |
Capex to depreciation | 0 | |
Stock based compensation to revenue | 0 | |
Graham number | 0 | |
ROIC | 0 | |
Return on tangible assets | 0 | |
Graham Net | 0 | |
Working capital | -1.23M | |
Tangible asset value | 20K | |
Net current asset value | -1.23M | |
Invested capital | 15 | |
Average receivables | 0 | |
Average payables | 0 | |
Average inventory | 0 | |
Days sales outstanding | 0 | |
Days payables outstanding | 0 | |
Days of inventory on hand | 0 | |
Receivables turnover | 0 | |
Payables turnover | 0 | |
Inventory turnover | 0 | |
ROE | 0 | |
Capex per share | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2021-06-30 for Q2
Metric | History | 2021-06-30 |
---|---|---|
2.02K | ||
Revenue per share | 0 | |
Net income per share | -0.62 | |
Operating cash flow per share | -0.01 | |
Free cash flow per share | -0.01 | |
Cash per share | 0 | |
Book value per share | 8.53 | |
Tangible book value per share | 8.53 | |
Share holders equity per share | 8.53 | |
Interest debt per share | 0 | |
Market cap | 1.72B | |
Enterprise value | 1.72B | |
P/E ratio | -4.02 | |
Price to sales ratio | 0 | |
POCF ratio | -745.66 | |
PFCF ratio | -745.66 | |
P/B Ratio | 1.17 | |
PTB ratio | 1.17 | |
EV to sales | 0 | |
Enterprise value over EBITDA | -16.09 | |
EV to operating cash flow | -745.64 | |
EV to free cash flow | -745.64 | |
Earnings yield | -0.06 | |
Free cash flow yield | 0 | |
Debt to equity | 0 | |
Debt to assets | 0 | |
Net debt to EBITDA | 0 | |
Current ratio | 0.21 | |
Interest coverage | 0 | |
Income quality | 0.02 | |
Dividend Yield | 0 | |
Payout ratio | 0 | |
Sales general and administrative to revenue | 0 | |
Research and developement to revenue | 0 | |
Intangibles to total assets | 0 | |
Capex to operating cash flow | 0 | |
Capex to revenue | 0 | |
Capex to depreciation | 0 | |
Stock based compensation to revenue | 0 | |
Graham number | 10.9 | |
ROIC | 0 | |
Return on tangible assets | -0.06 | |
Graham Net | -1.48 | |
Working capital | -3.72M | |
Tangible asset value | 1.47B | |
Net current asset value | -253.98M | |
Invested capital | 0 | |
Average receivables | 0 | |
Average payables | 0 | |
Average inventory | 0 | |
Days sales outstanding | 0 | |
Days payables outstanding | 0 | |
Days of inventory on hand | 0 | |
Receivables turnover | 0 | |
Payables turnover | 0 | |
Inventory turnover | 0 | |
ROE | -0.07 | |
Capex per share | 0 |
SRNG Frequently Asked Questions
What is Soaring Eagle Acquisition Corp. stock symbol ?
Soaring Eagle Acquisition Corp. is a US stock , located in New york of Ny and trading under the symbol SRNG
What is Soaring Eagle Acquisition Corp. stock quote today ?
Soaring Eagle Acquisition Corp. stock price is $1.74 today.
Is Soaring Eagle Acquisition Corp. stock public?
Yes, Soaring Eagle Acquisition Corp. is a publicly traded company.